Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2026
Sep 16, 2026
9:30 AM EDT
The appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board.
Sep 09, 2026
8:45 AM EDT
An interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET. Bloomberg TV is available in an estimated 73 million homes across the U.S.
Sep 03, 2026
8:00 AM EDT
Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, at Nasdaq's San Francisco headquarters. Anixa's presentation will be held at 3:40 PM PT with a breakout session to follow.
Aug 24, 2026
9:15 AM EDT
Management will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference being held September 9 – 11, 2026, in New York City.
Aug 18, 2026
8:45 AM EDT
Management will participate in the H.C. Wainwright 28 th Annual Global Investment Conference being held September 14 – 16, 2026.
Jul 14, 2026
8:33 AM EDT
IP Australia has issued a Notice of Acceptance for a new patent related to Anixa's breast cancer vaccine technology.
Jul 06, 2026
8:30 AM EDT
The first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Center ("Moffitt").
Jun 29, 2026
8:45 AM EDT
The Korean Ministry of Intellectual Property (MOIP) has issued Patent Number 10-2960889 related to Anixa's breast cancer vaccine technology. This composition-of-matter patent, exclusively licensed from Cleveland Clinic, protects the Company's novel approach to breast cancer prevention and treatment in South Korea…
Jun 26, 2026
9:10 AM EDT
Its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium this week.
Jun 11, 2026
9:05 AM EDT
Two of its clinical-stage immunotherapy programs will be presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium, being held June 22 – 23, 2026, at Memorial Sloan Kettering Cancer Center in New York City.
Jun 01, 2026
9:00 AM EDT
The Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.
May 11, 2026
11:48 AM EDT
Updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the Company's follicle-stimulating hormone receptor ("FSHR")-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.
May 01, 2026
9:15 AM EDT
An interview of Chairman and CEO, Dr. Amit Kumar, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, May 2, at 7pm ET. Bloomberg TV is available in an estimated 73 million homes across the U.S.
Apr 29, 2026
9:10 AM EDT
The Mexican Institute of Industrial Property (IMPI) has issued Patent Number 432748, covering key aspects of the Company's breast cancer vaccine technology.
Apr 22, 2026
8:45 AM EDT
Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center, will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, being held May 6 – 9, 2026, in Dublin, Ireland.
Apr 09, 2026
9:05 AM EDT
Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the upcoming RedChip Biotech Resurgence: Platforms and Pipelines of Today's Innovators virtual investor conference on April 16, 2026, at 3:30 pm ET.
Apr 07, 2026
8:55 AM EDT
Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the upcoming Water Tower Research (WTR) Insights Conference on April 14, 2026, at 12:30 pm ET.
Apr 06, 2026
9:10 AM EDT
Its Chairman and CEO, Dr. Amit Kumar, was recently featured in an interview on the Smart Money Circle program hosted by Adam Sarhan.
Apr 01, 2026
8:50 AM EDT
It has entered into a development and manufacturing agreement with Cytovance Biologics ( www.cytovance.com ), a leading full-service contract development and manufacturing organization ("CDMO") specializing in mammalian and microbially expressed biologics, to produce cGMP clinical materials for its planned Phase 2…
Mar 30, 2026
9:05 AM EDT
Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 trial, will be presenting at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, being held April 10 – 13, 2026, in…
